Industry lauds PDUFA VII focus on innovation, transparency

Trade associations in the pharmaceutical and biotechnology fields have weighed in on the performance goals FDA has outlined for the upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA VII), taking a generally favorable view of planned initiatives and areas of focus.